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Brief Communication  
 
 
Measures of Mortality in Coronavirus (COVID-19) Compared with 
SARS and MERS 
 
 




In late 2019, a novel coronavirus, now designated severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of an 
outbreak of acute respiratory illness in Wuhan, a city in China. Mortality rate, 
case fatality rate, and Years of Potential Life Lost can be measured by 
determining death cases. Much of our information on mortality rates of diseases 
can be obtained through a regular implementation of care plans that are often 
developed to screen infectious diseases. In the YLL component, the higher the 
individuals die at an earlier age, the longer their life is lost. For COVID-19, this 
component refers to the simple subtraction of age at death due to COVID-19 
from the standardized life expectancy for the same age in the same sex. A 
potential application of health summary indices is to consider the non-fatal 
consequences of diseases to ensure that they are taken into account in health 
policy making. Given that COVID-19 has a non-fatal effect on a large number 
of patients, the estimation of disease burden using the DALYs may be an 
appropriate index for achieving this goal.  
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In late 2019, a novel coronavirus, now 
designated severe acute respiratory syndrome 
coronavirus 2(SARS-CoV-2) was identified as the 
cause of an outbreak of acute respiratory illness in 
Wuhan, a city in China. In February 2020, the World 
Health Organization (WHO) named the disease 
COVID-19, which stands for coronavirus disease 
2019. The Covid-19 compared to previous outbreaks 
of severe acute respiratory syndrome (SARS-CoV) and 
Middle East respiratory syndrome (MERS) is more 
contagious. Since the first reports of COVID-19, 
infection has spread to include more than 80,000 cases 
in China and increasing cases worldwide, prompting 
the WHO to declare a public health emergency in 
January 2020 and characterize it as a pandemic in 
March 2020 (1-5) 
In accordance with the latest data published by 
the World Health Organization, since the first report of 
COVID-19 cases from Wuhan China to May 11, 2020, 
more than 4,006,257 confirmed cases of the disease 
and 278,892 death cases were reported in the world (6). 
However, despite the lower case fatality rate, covid-19 
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has so far resulted in more deaths than SARS and 
MERS combined (A total of 1,632 deaths; including 
774 deaths due to SARS and 858 deaths due to MERS) 
(7). Mortality rate “MR” (8), case fatality rate “CFR” 
(9), and Years of Potential Life Lost “YPLL” (8) can 
be measured using data on cases and deaths. Much of 
our information on mortality rate of diseases can be 
obtained through a regular implementation of care 
plans that are often developed to screen infectious 
diseases (10). Mortality Rate is the ratio of number of 
deaths from a particular cause to the size of the entire 
population at risk (both sick and healthy). The index 
represents the risk of death due to a specific reason in 
a defined population. Case fatality rate on the other 
hand is the ratio of individuals, who have died from a 
particular disease, to the total number of individuals 
with the disease at a certain time (usually expressed in 
percentage), indicating the risk of death in the patients. 
Case Fatality Rate can determine the severity of 
diseases and can thus help us determine how to 
improve the treatment methods over time. Basic 
reproductive number (R0) is a measure of the average 
number of infections caused by an infected person at 
the early stages of an epidemic in which all contacts 
are sensitive (11-13). The aim of this paper is 
comparison of measures of mortality in COVID-19. 
Changes in Case Fatality Rate in COVID-19 
Knowledge of the CFR is critical to characterize 
the severity and understand the pandemic potential of 
COVID-19 in the early stage of the epidemic. Using 
the exponential growth rate of the incidence, the 
present study statistically estimated the CFR and the 
basic reproduction number—the average number of 
secondary cases generated by a single primary case in 
a naïve population (14). Real or false changes can be 
seen in the fatality rate of COVID-19, whether 
increasing or decreasing, in a society or different 
geographical areas and subgroups of any society over 
time. The following table presents an estimate of case 
fatality rates in different countries on May 11, 2020 
(Table 1) (6). 
Results of studies in China indicated that 
factors, which cause actual changes in case fatality rate 
of COVID-19 include the patients' age (population 
composition), as the older ages (population aging) 
increases the fatality rate; and underlying diseases 
including (cardiovascular diseases, renal impairment 
Table 1: Reported deaths from COVID-19 on May 11, 2020. 
Estimated case 





4.37 7417 169575 Germany 
5.50 4643 84450 China 
6.05 76916 1271645 United States of America 
6.17 6640 107603 Iran (Islamic Republic of) 
6.81 10627 155939 Brazil 
6.95 4728 67996 Canada 
11.86 26621 224390 Spain 
12.76 5440 42627 Netherlands 
13.95 30560 219070 Italy 
14.53 31855 219187 The United Kingdom 
16.31 8656 53081 Belgium 
19.21 26338 137073 France 
Only countries with more than 4600 death cases are included. Data are from WHO (6) 
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(15, 16) diabetes, chronic respiratory diseases (17), 
hypertension, and cancer) (18-20). Having an effective 
drug to treat the infectious agent will reduce the case 
fatality rate, but there is currently no proven effective 
therapeutic drug for COVID-19; and other care and 
support methods are provided for hospital admissions 
(21). Factors, which may cause a false change in 
fatality rates in various diseases such as COVID-19 
include errors in disease diagnosis, changes in disease 
name coding, changes in disease classification, errors 
in counting, errors in classification of demographic 
variables including age (calculation of case fatality rate 
in age groups), errors in the proportion of at-risk 
groups (Calculation of case fatality rate in groups with 
underlying diseases) (13, 22, 23).  
Reporting communicable diseases is an 
essential element in control these diseases and quickly 
diagnosing epidemics (24). Hospitals are among the 
centers where patients visit and are even hospitalized. 
Hospitals can also be the starting point for an epidemic. 
Low awareness among the health care staff regarding 
the reporting system, high workload in hospitals, lack 
of a standard reporting system and incomplete 
documentation are the causes of incomplete reports of 
infectious diseases in hospitals. As a result, it is not so 
much easy to analyze and interpret information and use 
their results; so, the data could rarely be used for public 
health decision making (25). Possibly, it could be as 
one of the reasons for the differences in COVID-19 
case-fatality among different countries. 
Discussion 
Table 2 presents the criteria for susceptibility 
and mortality in COVID-19, MERS and SARS (7, 18-
23, 26-33). The higher the rates of transmission and 
fatality of a disease, the higher its mortality. According 
to Table 2 and Fig 1, fewer people in the world have 
become infected with MERS and SARS, resulting in 
fewer deaths despite their higher fatality rates, but due 
to lower transmission rates, but due to the higher rate 
of transmission in COVID-19, many people have 
Table 2: Comparison of epidemiological characteristics in COVID-19 ،MERS و   SARS. 
Results 
Disease and Epidemic Period 
Morbidity Index COVID-19 MERS SARS 
From 2020 2016  - 2012 2003  - 2002 
MERS< SARS< COVID-19 2-3 >1  1-2 Basic Reproductive Rate (R0) 
MERS< SARS< COVID-19 *4006257 2494 8096 Number of patients 
SARS < MERS < COVID-19 278892* 858 774 Number of death 
COVID-19 < SARS< MERS 6.9 % 34.4 % 9.6 % Case Fatality rate 
MERS< SARS< COVID-19 more than 210 27 29 Number of countries involved 
*Reported total confirmed cases and total deaths from COVID-19 on May 11, 2020. Data are from WHO (6)  
 
Figure 1. Comparison of Morbidity (Number of patients) and mortality (Number of death) in COVID-19 ،MERS, SARS. 
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become infected around the world, and despite lower 
fatality rates, it causes a large number of patients and 
more deaths. However, new travel facilities in 2020, 
especially for air travels, in comparison with the 
beginning of MERS (in 2002) and SARS (in 2012) 
epidemics, has accelerated the transmission of 
COVID-19 (2020), leading to its spread in a great 
number of countries around the world within two 
months. On the contrary, the preventive measures of 
governments and people during MERS, SARS and 
COVID-19 epidemics, including quarantine, home 
quarantine, social distance, and health care have all 
contributed to a decrease in the spread of diseases (34, 
35). 
Quality of Life and COVID-19: Figure 1 shows that 
COVID-19 has a non-fatal effect on patients compared 
to MERS and SARS. In other words, COVID-19 is a 
more non-fatal disease and despite the fact that its 
effect on people, who are recovered from the disease, 
is not a means of determining its mortality, its effect 
may be important in terms of human health 
considerations. The concept of quality of life includes 
dimensions of the overall quality of life that clearly 
affect the health (physical or mental). At the individual 
level, this concept includes feelings of physical and 
mental health and related issues, including the health 
risks and status, functional status (person), social 
support, and socio-economic status (36). Despite the 
fact that prioritizing resources in health care programs 
is often based on mortality rates, since COVID-19 is 
not deadly compared to similar diseases, it seems that 
patients' quality of life should be taken into account in 
developing a care plan. 
Disability-Adjusted Life Years and COVID-19: 
Disability-Adjusted Life Years (DALYs) refer to the 
sum of years of life lost due to premature mortality 
(YLL) and Years of life lost due to Disability (YLD) 
in society (8). 
 
DALYs = YLL + YLD 
 
In the YLL component, the higher the 
individuals die at an earlier age, the longer their life is 
lost (13). For COVID-19, this component refers to the 
simple subtraction of age at death due to COVID-19 
from the standardized life expectancy for the same age 
in the same sex. The total life loss in a society is thus 
the simple addition of YLLs of died people in that 
society. For the second component of the Disability-
Adjusted Life Years (DALY), namely Years of life lost 
due to Disability (YLD), we should study non-fatal 
effects of COVID-19, including disabilities; and its 
study seems to require a longer period than the 
beginning of the COVID-19 epidemic. A potential 
application of health summary indices is to consider 
the non-fatal consequences of diseases to ensure that 
they are taken into account in health policy making 
(37). Given that COVID-19 has a non-fatal effect on a 
large number of patients, the estimation of disease 
burden using the DALYs may be an appropriate index 
for achieving this goal. 
Conclusion 
A potential application of health summary 
indices is to consider the non-fatal consequences of 
diseases to ensure that they are taken into account in 
health policy making. Given that COVID-19 has a non-
fatal effect on a large number of patients, the 
estimation of disease burden using the DALYs may be 
an appropriate index for achieving this goal. 
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